Breaking Boundaries: Novel Effects of Levosimendan in Various Diseases

Hongyuan Zhang; Minxing Zhao; Yanrong Liu

doi:10.53941/ijddp.2024.100005

Abstract

Levosimendan, an inodilator that has been applied in clinical use for over two decades, has transcended its initial indication in the management of acutely decompensated chronic heart failure. Over the years, it has been adopted in septic shock, perioperative use of cardiac surgery, advanced end-stage heart failure, and has shown potential for inhaled administration, highlighting its versatility. Levosimendan has diverse mechanisms of action which mediate its non-traditional uses. Ongoing research aims to expand our understanding and develop personalized treatment strategies for the use of levosimendan. The significance of levosimendan in acute decompensated heart failure and cardiogenic shock, highlights its evolving role in contemporary cardiovascular medicine. This comprehensive review explores its pharmacodynamics, effects, and the challenges and opportunities it presents in various clinical settings. We describe levosimedan’s expanding usage, ranging from septic shock, intermittent intravenous in advanced heart failure, perioperative cardiac surgery and pulmonary hypertension management by inhaled levosimendan as well as its future prospects.

References

1.
Farmakis, D.; Alvarez, J.; Gal, T.B.; et al. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int. J. Cardiol. 2016, 222, 303‒312.
2.
Papp, Z.; Agostoni, P.; Alvarez, J.; et al. Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. J. Cardiovasc. Pharmacol. 2020, 76, 4‒22.
3.
Cholley, B.; Levy, B.; Fellahi, J.L.; et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit Care. 2019, 23, 1‒8.
4.
Antila, S.; Pesonen, U.; Lehtonen, L.; et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur. J. Pharm. Sci. 2004, 23, 213‒222.
5.
Conti, N.; Gatti, M.; Raschi, E.; et al. Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. Drug Des. Devel Ther. 2021, 15, 3391‒3409.
6.
Pan, J.; Yang, Y.M.; Zhu, J.Y.; et al. Multiorgan Drug Action of Levosimendan in Critical Illnesses. Biomed Res. Int. 2019. 2019, 9731467.
7.
De Backer, D.; Cecconi, M.; Chew, M.S.; et al. A plea for personalization of the hemodynamic management of septic shock. Crit Care. 2022, 26, 372.
8.
Guan, Q.; Zhang, C.; Li, B.; et al. Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy. Heart Surg. Forum 2023, 26, E609‒E620.
9.
Ravikumar, N.; Sayed, M.A.; Poonsuph, C.J.; et al. Septic Cardiomyopathy: From Basics to Management Choices. Curr. Probl. Cardiol. 2021, 46, 100767.
10.
Lima, M.R.; Silva, D. Septic cardiomyopathy: A narrative review. Revista Portuguesa de Cardiologia. 2023, 42, 471‒481.
11.
Gordon, A.C.; Perkins, G.D.; Singer, M.; et al. Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N. Engl. J. Med. 2016, 375, 1638‒1648.
12.
Meng, J.B.; Hu, M.H.; Lai, Z.Z.; et al. Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial. Med. Sci. Monit. 2016, 22, 1486‒1496.
13.
Ge, Z.; Gao, Y.; Lu, X.; et al. The association between levosimendan and mortality in patients with sepsis or septic shock: a systematic review and meta-analysis. Eur J Emerg Med. 2024, 31, 90‒97.
14.
Di Molfetta, P.; Gregorini, R.; Fiore, C.; et al. Is There Still Room for the Prophylactic Use of Levosimendan in Cardiac Surgery? Ann. Thorac. Surg. 2018, 106, 1590.
15.
Landoni, G.; Lomivorotov, V.; Silvetti, S.; et al. Nonsurgical Strategies to Reduce Mortality in Patients Undergoing Cardiac Surgery: An Updated Consensus Process. J. Cardiothorac. Vasc. Anesth. 2018, 32, 225‒235.
16.
Landoni, G.; Lomivorotov, V.V.; Alvaro, G.; et al. Levosimendan for Hemodynamic Support after Cardiac Surgery. N. Engl. J. Med. 2017, 376, 2021‒2031.
17.
Mehta, R.H.; Leimberger, J.D., van Diepen, S.; et al. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N. Engl. J. Med. 2017, 376, 2032‒2042.
18.
Faisal, S.A.; Apatov, D.A.; Ramakrishna, H.; et al. Levosimendan in Cardiac Surgery: Evaluating the Evidence. J. Cardiothorac. Vasc. Anesth. 2019, 33, 1146‒58.
19.
Ayala, R.; Gewehr, D.M.; Godoi, A.; et al. Preoperative Levosimendan in Patients with Severe Left Ventricular Dysfunction Undergoing Isolated Coronary Artery Bypass Grafting: A Meta-Analysis of Randomized Controlled Trials. J. Cardiothorac. Vasc. Anesth. 2024, 38, 649‒659.
20.
Crespo-Leiro, M.G.; Metra, M.; Lund, L.H.; et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018, 20, 1505‒1535.
21.
Ferreira Reis, J.; Valentim Goncalves, A.; Ilhao Moreira, R.; et al. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions. Rev Port Cardiol. 2023, 42, 335‒343.
22.
Altenberger, J.; Parissis, J.T.; Costard-Jaeckle, A.; et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: A multicentre randomized trial. Eur. J. Heart Fail. 2014, 16, 898‒906.
23.
Tycinska, A.; Gierlotka, M.; Bartus, S.; et al. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Adv. Med. Sci. 2022, 67, 18‒22.
24.
Oliva, F.; Perna, E.; Marini, M.; et al. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration. Int. J. Cardiol. 2018, 272, 255‒259.
25.
Garcia-Gonzalez, M.J.; Aldea Perona, A.; Lara Padron, A.; et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study. ESC Heart Fail. 2021, 8, 4820‒4831.
26.
Comin-Colet, J.; Manito, N.; Segovia-Cubero, J.; et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur. J. Heart Fail. 2018, 20, 1128‒1136.
27.
Oliva, F.; Comin-Colet, J.; Fedele, F.; et al. Repetitive levosimendan treatment in the management of advanced heart failure. Eur. Heart J. Suppl. 2018, 20, I11‒I20.
28.
Codina, P.; Dobarro, D.; de Juan-Baguda, J.; et al. Heart failure risk scores in advanced heart failure patients: insights from the LEVO-D registry. ESC Heart Fail. 2023, 10, 2875‒2881.
29.
Masarone, D.; Valente, F.; Verrengia, M.; et al. Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience. J. Cardiovasc. Med. 2020, 21, 919‒921.
30.
Polzl, G.; Allipour Birgani, S.; Comin-Colet, J.; et al. Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Fail. 2019, 6, 174‒181.
31.
Silvetti, S.; Pollesello, P.; Belletti, A. Repeated Levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality. J. Cardiovasc. Pharmacol. 2024, 83, 144–157.
32.
Hansen, M.S.; Andersen, A.; Nielsen-Kudsk, J.E. Levosimendan in pulmonary hypertension and right heart failure. Pulm. Circ. 2018, 8, 2045894018790905.
33.
Kundra, T.S.; Nagaraja, P.S.; Bharathi, K.S.; et al. Inhaled levosimendan versus intravenous levosimendan in patients with pulmonary hypertension undergoing mitral valve replacement. Ann. Card. Anaesth. 2018, 21, 328‒332.
34.
Evans, M.A.; Suresh, S. Inhaled levosimendan: New opportunities with an old drug. J. Clin. Anesth. 2021, 73, 110337.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us